Apo-Amitriptyline

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Apo-Amitriptyline

Property Description
Active ingredient Amitriptyline hydrochloride
Form Tablet (Oral dosage form)
Pharmacological class Tricyclic Antidepressant (TCA)
Common use Alleviating emotional imbalance and distress
Origin Synthetic (Dibenzocycloheptadiene derivative)

What Type of Medicine is Apo-Amitriptyline?

Apo-Amitriptyline is a prescription-only pharmaceutical preparation that belongs to the pharmacological class of Tricyclic Antidepressants (TCAs), a group clinically recognized for its foundational role in psychopharmacology. This medication is a specific trade name for the active substance, Amitriptyline hydrochloride, a key entity in the broader group of Antidepressive Agents. As a single-ingredient product, Apo-Amitriptyline is utilized to address symptoms associated with emotional imbalance and profound distress, particularly in adult patients. Amitriptyline is an established antidepressant agent. This classification is vital, as the TCA profile offers physicians a proven strategy when comprehensive neurochemical modulation is necessary for therapeutic stability.

Composition, Origin, and Pharmaceutical Form

High-Level Purpose and Mechanism Principle

The core component is Amitriptyline hydrochloride, a chemical substance that is structurally defined as a tertiary amine and a dibenzocycloheptadiene derivative. This chemical structure confirms its entirely synthetic origin. Apo-Amitriptyline is commonly available as an oral dosage form in tablets, intended for oral administration. The composition of the tablet includes the potent active ingredient combined with the necessary solid excipients to ensure a stable and consistent delivery of the medicine.

The general purpose of Apo-Amitriptyline is to alleviate psychological distress and stabilize mood by modulating key chemical messengers in the brain. This therapeutic action is achieved via the drug's core mechanism principle, which involves balancing the availability of the neurotransmitters serotonin and norepinephrine at the neuronal level. Amitriptyline works by correcting the balance of natural substances in the brain that are necessary for mental health. Additionally, this medication has an inherent sedative effects profile and distinct anticholinergic properties, which further contribute to promoting mental tranquility and relaxation alongside its mood-stabilizing action.

What side effects are possible with Apo-Amitriptyline?

Possible Side Effects and Safety Information

Official regulatory documents define the safety profile of Apo-Amitriptyline (Amitriptyline) by grouping adverse reactions into categories of frequency and system involvement, along with several important safety warnings.

Critical Safety Warnings

Suicidal Ideation and Behavior (Boxed Warning): Antidepressants, including this medication, carry a Boxed Warning for increased risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (up to 24 years of age) during initial treatment or dose changes. Worsening depression or unusual changes in behavior should be monitored closely.

Contraindications: The medication is formally restricted for use with or within 14 days of taking a Monoamine Oxidase Inhibitor (MAOI) due to the risk of severe, potentially fatal Serotonin Syndrome. It is also contraindicated during the acute recovery phase following a myocardial infarction.

Adverse Reaction Profile

Adverse reactions commonly involve the Central Nervous System (CNS) and have a strong anticholinergic component. Common side effects include dry mouth (xerostomia), drowsiness, constipation, blurred vision, dizziness, and headache. These are often transient.

Serious or Clinically Significant Reactions include life-threatening cardiac arrhythmias (such as QT prolongation), myocardial infarction, stroke, exacerbation of narrow-angle glaucoma, seizures, and the potential for inducing hypomania or mania in susceptible individuals. Hypersensitivity reactions and blood disorders (e.g., agranulocytosis) are rare but documented.

Population-Specific Concerns require caution in the elderly, who are at increased risk for anticholinergic effects, confusion, falls, and low sodium levels (hyponatremia). Dose adjustments are necessary for elderly patients due to altered metabolism. The medication is generally not recommended for use in children under 12 years of age.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Apo-Amitriptyline (Amitriptyline) is considered very serious and potentially life-threatening, requiring immediate emergency medical intervention. Toxicity effects can develop rapidly, often within 30 minutes to a few hours after ingestion.

Documented Overdose Manifestations

Official regulatory information describes severe effects involving the cardiovascular, central nervous, and respiratory systems. Immediate life-threatening presentations include:

  • Cardiac Dysrhythmias: Severe, irregular heart rhythms, which can be fatal.
  • Hypotension: Dangerously low blood pressure.
  • Coma and Seizures
  • Respiratory Depression: Slowed or stopped breathing.

Other symptoms may include muscle rigidity, vomiting, confusion, stupor, and central and peripheral anticholinergic effects (such as dilated pupils and dry mouth). Due to the high risk of fatal outcomes from cardiovascular collapse or lethal arrhythmia, prompt emergency response is mandatory.

Required Emergency Action

Immediate medical help is required right away if an overdose has occurred or is suspected. This is necessary even if initial symptoms appear mild or are absent, due to the potential for rapid progression to critical states. Overdose management must be handled in a hospital setting, typically involving continuous cardiac monitoring and supportive care. Specific treatments, such as intravenous sodium bicarbonate, may be required to manage severe cardiotoxicity.

Therapeutic Uses of Apo-Amitriptyline

What Apo-Amitriptyline Treats: Main Uses and Benefits

Apo-Amitriptyline (amitriptyline) is considered relevant across several core therapeutic domains, applied across conditions where symptoms may intensify temporarily or create noticeable functional strain. Relevant therapeutic areas include addressing symptoms of Major Depressive Disorder, providing supportive relief for various types of neuropathic pain, and assisting with the prophylactic management of migraines and chronic tension-type headaches.

The medication supports patients primarily by helping to manage symptom clusters that may become intense or disruptive, such as profound emotional distress and persistent burning nerve sensations. It is commonly used in clinical settings where supportive symptom management is appropriate to maintain functional stability.

“It is relevant when complex symptoms, such as pain-related sleep disturbances, interfere with daily comfort.”

In specialized scenarios, it may also be part of symptomatic management for specific patient groups, such as children (aged 6 years and above) with nocturnal enuresis. This therapeutic approach contributes to easing the overall symptom load during difficult symptomatic phases.

Quick Fact: Support for Neuropathic Pain
This medication is applied across therapeutic domains involving chronic, persistent burning, shooting, or stabbing pain that is typically nerve-mediated.

Eligibility and Restrictions for Use

Regulatory documents explicitly define which populations are eligible to use Apo-Amitriptyline and which are strictly prohibited. The medicine is primarily for adult patients (18 years and older) for general psychiatric and pain indications. Its use is contraindicated in several conditions and populations:

  • Cardiovascular Conditions: Patients in the acute recovery phase following a myocardial infarction, or those with any degree of heart block, arrhythmias, or severe coronary artery disease must not use the medicine.
  • Concomitant Therapy: Use is prohibited if a patient is taking, or has taken within the last 14 days, a Monoamine Oxidase Inhibitor (MAOI).
  • Organ Function and Hypersensitivity: The medicine is contraindicated in cases of severe liver disease and in patients with known hypersensitivity to the active ingredient or excipients.

Restrictions by Age and Physiological State

Population Group Eligibility Status (Regulatory Wording)
Pediatric Patients Contraindicated for depression in children under 12 years (in some regions, under 18 for general use). Approved only for nocturnal enuresis in those 6 years and older.
Older Adults (Geriatric) Use requires careful monitoring and lower starting doses due to increased sensitivity and risk of adverse effects.
Pregnancy Not recommended unless the potential benefit justifies the risk to the fetus.
Lactation (Breastfeeding) Not recommended as the substance is excreted into breast milk.

Eligibility is further restricted for those with pre-existing conditions such as narrow-angle glaucoma, urinary retention, or a history of epilepsy; use in these populations requires caution.

What should I know about interactions with other medicines?

The use of Apo-Amitriptyline with other medicinal products carries several significant interaction risks.

Contraindicated Combinations

The most serious restriction is the contraindication with Monoamine Oxidase Inhibitors (MAOIs), which include isocarboxazid, phenelzine, and selegiline, as well as linezolid and intravenous methylene blue. This combination can lead to a potentially fatal Serotonin Syndrome, characterized by hyperpyrexia, severe convulsions, and coma. A minimum 14-day washout period is mandatory when switching between Apo-Amitriptyline and any MAOI.

Pharmacodynamic and Pharmacokinetic Interactions

Concomitant use with Central Nervous System (CNS) depressants, including alcohol, barbiturates, benzodiazepines, and narcotic pain relievers, is subject to caution as it can lead to additive CNS depression, increasing sedation and respiratory risk.

Anticholinergic agents (e.g., certain antiparkinsonian drugs) also pose a risk of additive anticholinergic effects like severe constipation or urinary retention.

Apo-Amitriptyline's metabolism is significantly affected by Cytochrome P450 enzymes (CYP2D6, CYP3A4). Inhibitors of these enzymes, such as certain SSRIs (e.g., fluoxetine, paroxetine) and cimetidine, can increase plasma levels of Apo-Amitriptyline, raising the risk of toxicity, while enzyme inducers (e.g., carbamazepine, phenobarbital) may potentially reduce its effectiveness. The drug may also block the antihypertensive effect of certain blood pressure medications (e.g., guanethidine, clonidine) and increase the risk of cardiac arrhythmias when combined with thyroid medication.

Mechanism of Action

Apo-Amitriptyline (amitriptyline) works through several key mechanisms involving neurotransmitter modulation and receptor binding, resulting in altered central nervous system activity.


Modulation of Monoamine Neurotransmission

Apo-Amitriptyline primarily inhibits the reuptake of two key signaling molecules, norepinephrine and serotonin, at presynaptic terminals. This action increases the concentration of these monoamines in the synaptic cleft, potentiating their effects on postsynaptic neurons. This enhanced signaling modulates neurotransmitter activity in descending pathways involved in pain signal processing and affective regulation.


Antagonism of Receptor-Mediated Signaling

The drug acts within domains involving several non-monoamine receptors. It has strong affinity for and blocks muscarinic cholinergic receptors (M1), histamine H1 receptors, and alpha1-adrenergic receptors. Blocking the H1 receptor results in H1 receptor-mediated central nervous system depression, while anticholinergic activity at the muscarinic receptors induces M1 receptor-mediated anticholinergic effects in peripheral tissues.


Influence on Ion Channel Function

Apo-Amitriptyline engages mechanisms that regulate neuronal excitability by acting as a blocker of certain voltage-gated sodium channels. By stabilizing the resting state of nerve cell membranes and inhibiting the flow of ions required for firing, it reduces neuronal excitability by inhibiting the function of voltage-gated sodium channels.

Dosage and Administration Information

How to Use Apo-Amitriptyline

Apo-Amitriptyline is officially administered through the oral route as a tablet, which must be swallowed whole with water and may be taken with or without food. The administration schedule is typically structured around a once-daily pattern, frequently advised to be taken at bedtime due to the drug’s inherent properties.

Dosing must follow a principle of gradual titration, where therapy begins at a low initial dose and is increased slowly, often in small increments over several days. Standard adult outpatient doses typically range up to 150 mg daily, though higher daily limits (up to 300 mg) are recognized for supervised inpatient use.

Specific adjustments are required for certain patient groups. Older adults (aged 65 years and above) and individuals with cardiovascular issues typically start on a significantly lower daily dose, often between 10 mg and 25 mg. For the approved use in pediatric nocturnal enuresis, a defined daily dose must be administered one to one and a half hours before bedtime.

The treatment protocol includes defined timeframes. If a dose is missed, standard procedure involves skipping the missed dose if it is almost time for the next scheduled dose, and never taking a double dose. Treatment should continue for a substantial maintenance period (e.g., a minimum of three months) after initial response. When therapy needs to conclude, it must be performed by gradually tapering the dose over time, rather than stopping abruptly. These steps define the standardized way the medicine is authorized to be used.

Recent Clinical Evidence

Apo-Amitriptyline: Recent Clinical Evidence

This section summarizes clinical evidence for the uses of amitriptyline, an agent originally developed as a tricyclic antidepressant (TCA).


Primary Indication: Depression and Pain

Clinical trials have long established the use of amitriptyline in Major Depressive Disorder (MDD). Recent studies reinforce its role as a potential second-line therapy for depression following the failure of initial treatments, though data suggests newer antidepressants may have a more favorable tolerability profile.

Evidence also supports its use in Neuropathic Pain, including painful diabetic neuropathy and post-herpetic neuralgia. Low-dose amitriptyline has been systematically studied in these pain conditions, where it is often considered a first- or second-line option in clinical guidelines. This effect is generally observed at lower doses than those typically required for managing depression.


Chronic Pain and Headache Prophylaxis

Research has explored the use of amitriptyline for other chronic conditions. For Chronic Low Back Pain, one randomized clinical trial noted a statistically significant improvement in disability outcomes at the 3-month mark, though no significant difference in pain reduction was found at the 6-month endpoint. Overall data suggests a small but statistically significant role in chronic musculoskeletal pain management.

For headache prophylaxis, evidence supports the use of amitriptyline for the prevention of periodic migraine in adults and the reduction of frequency and duration of chronic tension-type headaches.


Safety and Tolerability

Amitriptyline's safety profile is a key focus in comparative research. Studies indicate that while the drug demonstrates effectiveness in certain conditions, it is generally associated with a higher burden of adverse effects compared to some newer agents. Common side effects reported across trials include dry mouth and drowsiness. The risk of serious side effects, particularly those affecting the heart, is monitored, and is a factor in dose selection and patient screening.

Key Studies & References

  1. Drug Monograph: Amitriptyline (Health Canada or similar regulatory body)

Frequently Asked Questions (FAQ)

Common questions about Apo-Amitriptyline (FAQ)


Q: How does Apo-Amitriptyline work to help with nerve pain?

Studies indicate that the drug's mechanism of action involves ‘turning down’ increased pain signals by correcting the balance of certain neurotransmitters (like norepinephrine and serotonin) in the nervous system. It also stabilizes nerve cell membranes, which helps reduce overactive electrical signalling. These combined effects modulate how pain signals reach the brain.


Q: Why do people say Apo-Amitriptyline helps with sleep?

Apo-Amitriptyline possesses sedative properties that are often utilized when the drug is taken at night. This effect is primarily due to the drug blocking histamine ( H1) receptors in the body, which leads to central nervous system (CNS) depression, or drowsiness. This can promote tranquility and relaxation alongside its other therapeutic actions.


Q: Is drowsiness or sedation a guaranteed side effect of Apo-Amitriptyline?

Drowsiness and sedation are listed in official product information as very common or common side effects, indicating they are commonly reported adverse reactions in clinical settings. However, official information does not imply that any side effect is guaranteed for every individual.


Q: What are the possible physical symptoms if Apo-Amitriptyline is stopped too quickly?

If the medication is stopped abruptly, regulatory guidance states that patients may experience withdrawal symptoms such as nausea, headache, and tiredness or lack of energy. Official guidance mandates that the dose is typically reduced gradually over time, rather than stopped abruptly, as part of the overall treatment plan.


Q: Can Apo-Amitriptyline be used by people who have a history of seizures?

The medication is known to be associated with a risk of seizures. Official product information indicates that patients who have a history of epilepsy or seizures require caution and close monitoring as described in the official product information.


Q: Does Apo-Amitriptyline affect blood pressure?

Official information indicates that the medication has been associated with both high or low blood pressure in some patients. Furthermore, it may block the antihypertensive effect of certain medications prescribed to manage blood pressure.


Q: How is the long-term effectiveness of Apo-Amitriptyline described in studies?

Evidence supports its long-term role for conditions like chronic insomnia and neuropathic pain, often showing sustained effects when combined with other therapies. However, official regulatory documentation emphasizes that tolerability must be monitored over time to ensure continued benefit.


Q: Can Apo-Amitriptyline interfere with driving or operating machinery?

Due to common side effects like drowsiness, dizziness, and blurred vision, official regulatory warnings state that individuals are advised to avoid driving, cycling, or operating heavy machinery until the effects of the medication are known.


Q: Can I take Apo-Amitriptyline if I have angle-closure glaucoma?

Official regulatory documents indicate that the medication is either contraindicated or requires caution for patients with narrow-angle glaucoma. This is due to the drug's anticholinergic properties which have the potential to worsen the condition.


Q: What is the difference in side effects between low doses and high doses of Apo-Amitriptyline?

The doses used for chronic pain conditions are typically lower than those used for treating major depression. Official information indicates that common side effects tend to occur less frequently or may be less intense at the lower dosage ranges.


Q: Why is it important to have regular check-ups while taking Apo-Amitriptyline?

Regular check-ups are necessary because the drug carries a Boxed Warning regarding the increased risk of suicidal thoughts and behaviors in young adults during initial treatment. Check-ups also allow a healthcare provider to assess your response to the medicine and monitor for potential side effects using laboratory tests.


Q: Is Apo-Amitriptyline the same as Elavil or other brand names?

Elavil is a common brand name under which the active ingredient, amitriptyline hydrochloride, was previously marketed in the United States. Apo-Amitriptyline is another trade name for the same medication, which is now widely available in generic form.


Q: How long does it typically take to feel the initial effects of Apo-Amitriptyline?

Official information on the drug’s physical characteristics states that maximum plasma levels are reached in about four hours following a dose. The drug’s characteristics indicate that a steady-state concentration in the bloodstream is typically reached within one week of consistent dosing.


Q: Can Apo-Amitriptyline cause weight gain?

Yes, weight changes are among the reported potential side effects listed in official product labeling. Both weight gain and weight loss have been reported in association with the use of this medication.


Q: Are there specific symptoms that should prompt immediate contact with a healthcare provider while taking Apo-Amitriptyline?

Official regulatory guidance identifies several symptoms that may indicate a serious reaction and warrant immediate medical attention. These include a slow or irregular heartbeat, seizures, severe swelling of the face and tongue, difficulty breathing, or unusual bleeding or bruising.


Q: Is Apo-Amitriptyline considered an addictive medication?

The medication is not generally considered physically addictive like controlled substances such as opioids. However, individuals may still experience withdrawal symptoms or psychological dependence, and regulatory documents describe the necessary process of gradual dose tapering when concluding treatment.


Q: Can Apo-Amitriptyline cause feelings of restlessness or anxiety when first starting?

Agitation, anxiety, and restlessness are listed in official product labeling as potential adverse effects. These feelings are potential adverse effects, and official guidance highlights the importance of monitoring behavioral changes during the initial treatment phase.


Q: Does Apo-Amitriptyline interact with common over-the-counter pain relievers?

Official guidance indicates that commonly available pain relievers such as paracetamol and ibuprofen may be taken for headaches while on this treatment. Official drug documentation advises consultation with a healthcare professional regarding the co-administration of any new medication, including OTC products.


Q: Is there an interaction between Apo-Amitriptyline and herbal supplements like St. John's Wort?

Official drug interaction information specifically notes that St. John's wort can increase the risk of side effects, including the rare but serious condition known as Serotonin Syndrome. Regulatory information indicates that concomitant use of St. John's wort is generally discouraged due to the potential for increased risks.


Q: Does Apo-Amitriptyline interact with blood thinners?

Yes, official sources note that Apo-Amitriptyline may increase the risk of bleeding when used with certain oral anticoagulants, such as warfarin. For this reason, regulatory guidance requires close monitoring and potential dose adjustment when these medications are used concurrently.


Q: Is it normal to experience vivid dreams or nightmares while taking Apo-Amitriptyline?

Nightmares or unusually vivid dreams are documented as possible side effects of this medication in official product labeling. This is a common form of sleep disturbance reported by some patients.


Q: Does Apo-Amitriptyline affect a person's libido or sexual function?

Changes in sex drive or ability are reported side effects of Apo-Amitriptyline. Official documents list both an increase or decrease in libido, as well as erectile dysfunction, as possible adverse events.


Q: What are the reported effects of Apo-Amitriptyline on a person's appetite?

Official product information includes changes in appetite as a potential side effect. This may manifest as either a decrease or increase in a person's desire to eat, which can contribute to the reported weight changes.


Q: What is the research status of Apo-Amitriptyline for fibromyalgia pain?

Systematic reviews of clinical evidence for fibromyalgia suggest there is very low-quality evidence for a major benefit in reducing pain for most patients. However, the drug is considered a first-line treatment in some guidelines and may provide substantial relief for a minority of patients.


Q: How long does Apo-Amitriptyline stay in your system after the last dose?

The elimination half-life of Apo-Amitriptyline is approximately 25 hours. Due to this relatively long half-life, it takes several days (about five half-lives) for the substance to be fully cleared from the body after the last dose.


Q: Is it true that Apo-Amitriptyline can increase sun sensitivity?

Yes, photosensitivity (increased sensitivity to sunlight) has been documented in clinical reviews as a possible skin reaction associated with this class of drug. Therefore, precautions against sun exposure, such as wearing protective clothing, are often noted in associated patient information.


Q: Are there differences between the generic Apo-Amitriptyline and the original brand-name drug?

Generic versions of the drug must be approved to contain the same active ingredient in the same strength and dosage form as the original brand-name drug. Regulatory bodies confirm generics are required to show they are biologically equivalent.

How should Apo-Amitriptyline be stored and disposed of?

How to Store and Dispose of Apo-Amitriptyline

The storage and disposal requirements for Apo-Amitriptyline (amitriptyline hydrochloride) tablets are strictly defined by regulatory documents to maintain product quality and safety.


Storage Conditions

Apo-Amitriptyline must be stored at Controlled Room Temperature, defined as 20^circ to 25 C (68^circ to 77 F), with permitted temperature excursions up to 30 C (86 F). The medication must be kept in a tight, light-resistant container, which should remain tightly closed when not in use. Stability requires protection from light and storage away from moisture.


Handling and Disposal

The most important safety requirement is to always keep the tablets out of the reach of children. Unused or expired Apo-Amitriptyline must be disposed of according to local regulations as specified in the official labeling, which ensures proper pharmaceutical waste handling procedures are followed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Apo-Amitriptyline found in:

A-Z Index: